INDIA- Roche Pharma India in association with Sidney Kimmel Cancer Center (SKCC) has launched an Advanced Certification Program in Molecular Oncology (ACMO) to equip oncologists and pathologists in the country with methods of genomic medicine.
Among the partners is BioQuest Solutions Pvt. Ltd which provides Cutting Edge Strategies, Innovative Solutions, and Knowledge Services to Pharmaceutical, Biotech & Device Organizations, and the Consumer Health Industry.
The pharmaceutical business stated in a release that this program would train roughly 100 healthcare experts from across the nation, including 30 pathologists and 70 oncologists.
The curriculum, which consists of 14 online modules and lasts for eight months, aims to deliver thorough, evidence-based updates on personalized medicine.
Professors from a variety of Thomas Jefferson University disciplines, including oncology, urology, computational medicine, biochemistry, and molecular biology, will serve as members of the program’s faculty.
“Understanding what makes people different – genetics, environment, lifestyle – is central to shifting the focus of healthcare from treating diseases to delivering the best care for each person throughout their lives,” V. Simpson Emmanuel, Roche Pharma India Managing Director & CEO said.
He noted that the ACMO offered by the SKCC – Jefferson Health will help equip their Oncologists and Pathologists with the subject matter expertise and methods of precision oncology to bring the desired change to individualized patient care.
Currently, Roche is the top provider of oncology care in India. In addition to cancer treatment, Roche also offers cutting-edge drugs for transplantation, rheumatoid arthritis (RA), and anemia linked to chronic kidney disease (CKD).
Precision oncology is focused on evaluating a person’s genetic profile to choose the optimal therapeutic option and could assist in determining whether or not treatment would be helpful for the patient.
In 2020, Roche signed a distribution agreement with Cipla to expand the scope of the partnership to include, the marketing and distribution of its trademark oncology drugs – Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova) in India.
Roche has dedicated itself for more than 60 years to improving the lives of people in India.
Currently, Roche is the top provider of oncology care in India. In addition to cancer treatment, Roche also offers cutting-edge drugs for transplantation, rheumatoid arthritis (RA), and anemia linked to chronic kidney disease (CKD).
Roche is dedicated to providing patients in India with the newest, most cutting-edge medications as quickly as possible.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
